In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel

Journal of Controlled Release

Volumn 104, Issue 1, 2005, Pages 181-191

  Ho, Emmanuel A ^a   Vassileva, Vessela ^a   Allen, Christine ^a   Piquette Miller, Micheline ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomaterials; Chemotherapy; Chitosan; Ovarian cancer; Sustained release

Indexed keywords

BIOCOMPATIBILITY; CELLS; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; MEDICAL PROBLEMS; ONCOLOGY; POLYMERS; TUMORS;

CELL MORPHOLOGY; CHITOSAN; OVARIAN TUMORS; PACLITAXEL (PTX);

IMPLANTS (SURGICAL);

CHITOSAN; LIPID; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLYMER;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG FECES LEVEL; DRUG IMPLANT; DRUG URINE LEVEL; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

EID: 18144413904     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.02.008     Document Type: Article

References (34)

1. R. Ozols, B. Bundy, B. Greer, J. Fowler, D. Clarke-Pearson, R. Burger, R. Mannel, K. DeGeest, E. Hartenbach, and R. Baergen Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 21 17 2003 3194 3200
2. A. du Bois, H. Luck, W. Meier, H. Adams, V. Mobus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schroder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, and J. Pfisterer A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 17 2003 1320 1329
3. J. Sandercock, M. Parmar, V. Torri, and W. Qian First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence Br. J. Cancer 87 8 2002 815 824
4. W. Kuhn Therapy for recurrent ovarian cancer Curr. Womens Health Rep. 3 1 2003 33 38
5. D. Armstrong Relapsed ovarian cancer: challenges and management strategies for a chronic disease Oncologist 7 Suppl. 5 2002 20 28
6. T. Herzog, R. Holloway, and G. Stuart Workshop: options for therapy in ovarian cancer Gynecol. Oncol. 90 3 Pt. 2 2003 S45 S50
7. R. Agarwal, and S. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev., Cancer 3 7 2003 502 516
8. L. Almadrones Treatment advances in ovarian cancer Cancer Nurs. 26 6 Suppl. 2003 16S 20S
9. P. Vasey Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies Br. J. Cancer 89 Suppl. 3 2003 S23 S28
10. M. Miller, and I. Ojima Chemistry and chemical biology of taxane anticancer agents Chem. Rec. 1 2001 195 211
11. M. Friedrich, D. Diesing, C. Villena-Heinsen, R. Felberbaum, H. Kolberg, and K. Diedrich Taxanes in the first-line chemotherapy of metastatic breast cancer: review Eur. J. Gynaecol. Oncol. 25 1 2004 66 70
12. R. Keresztes, J. Port, M. Pasmantier, R. Korst, and N. Altorki Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial J. Thorac. Cardiovasc. Surg. 126 5 2003 1603 1608
13. E. Bajetta, M. Del Vecchio, C. Bernard-Marty, M. Vitali, R. Buzzoni, O. Rixe, P. Nova, S. Aglione, S. Taillibert, and D. Khayat Metastatic melanoma: chemotherapy Semin. Oncol. 29 5 2002 427 445
14. C. Spencer, and D. Faulds Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer Drugs 48 5 1994 794 847
15. A. Sparreboom, O. van Tellingen, W. Nooijen, and J. Beijnen Tissue distribution, metabolism and excretion of paclitaxel in mice Anti-Cancer Drugs 9 1998 1 17
16. R. Weiss, R. Donehower, P. Wiernik, T. Ohnuma, R. Gralla, D. Trump, J. Baker Jr., D. Van Echo, D. Von Hoff, and B. Leyland-Jones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1990 1263 1268
17. S. Kim, D. Kim, Y. Shim, J. Bang, H. Oh, S. Wan Kim, and M. Seo In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Control. Release 72 1-3 2001 191 202
18. J. Jackson, X. Zhang, S. Llewellen, W. Hunter, and H. Burt The characterization of novel polymeric paste formulations for intratumoral delivery Int. J. Pharm. 270 1-2 2004 185 198
19. T. Hickey, D. Kreutzer, D. Burgess, and F. Moussy In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices J. Biomed. Mater. Res. 61 2 2002 180 187
20. S. Fulzele, P. Satturwar, and A. Dorle Study of the biodegradation and in vivo biocompatibility of novel biomaterials Eur. J. Pharm. Sci. 20 1 2003 53 61
21. J. Grant, M. Piquette-Miller, C. Allen, Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel, J Pharm Sci (in press).
22. M. Guminska, J. Ignacak, and E. Wojcik In vitro inhibitory effect of chitosan and its degradation products on energy metabolism in ehrlich ascites tumour cells (EAT) Pol. J. Pharmacol. 48 5 1996 495 501
23. M. Hasegawa, K. Yagi, S. Iwakawa, and M. Hirai Chitosan induces apoptosis via caspase-3 activation in bladder tumor cells Jpn. J. Cancer Res. 92 4 2001 459 466
24. L. Wang, E. Khor, A. Wee, and L. Lim Chitosan-alginate PEC membrane as a wound dressing: assessment of incisional wound healing J. Biomed. Mater. Res. 63 5 2002 610 618
25. P. Vande Vord, H. Matthew, S. DeSilva, L. Mayton, B. Wu, and P. Wooley Evaluation of the biocompatibility of a chitosan scaffold in mice J. Biomed. Mater. Res. 59 3 2002 585 590
26. A. Sharma, E. Mayhew, L. Bolcsak, C. Cavanaugh, P. Harmon, A. Janoff, and R. Bernacki Activity of paclitaxel liposome formulations against human ovarian tumor xenografts Int. J. Cancer 71 1 1997 103 107
27. A. Shikanov, B. Vaisman, M. Krasko, A. Nyska, and A. Domb Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: in vitro release and in vivo toxicity J. Biomed. Mater. Res. 69A 1 2004 47 54
28. C. Fournier, B. Hecquet, P. Bouffard, M. Vert, A. Caty, M. Vilain, L. Vanseymortier, S. Merle, A. Krikorian, and J. Lefebvre Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors Cancer Res. 51 19 1991 5384 5391
29. R. Ratner Reducing capsular thickness and enhancing angiogenesis around implant drug release systems J. Control. Release 78 1-3 2002 211 218
30. J. Babensee, R. Cornelius, J. Brash, and M. Sefton Immunoblot analysis of proteins associated with HEMA-MMA microcapsules: human serum proteins in vitro and rat proteins following implantation Biomaterials 19 7-9 1998 839 849
31. E. Fournier, C. Passirani, C. Montero-Menei, and J. Benoit Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility Biomaterials 24 19 2003 3311 3331
32. K. Athanasiou, G. Niederauer, and C. Agrawal Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers Biomaterials 17 2 1996 93 102
33. K. Fu, D. Pack, A. Klibanov, and R. Langer Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres Pharm. Res. 17 1 2000 100 106
34. M. Taylor, A. Daniels, K. Andriano, and J. Heller Six bioabsorbable polymers: in vitro acute toxicity of accumulated degradation products J. Appl. Biomater. 5 2 1994 151 157